Karan S. Dixit

Karan S. Dixit

Hematology | Oncology

675 N St Clair St Ste 20-100
Galter Pavilion
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.

Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 24, 2026

Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma.

Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma.

Journal: JCI insight

Published: February 03, 2026

Immunotherapy in Patients With Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: A Multi-institutional Case Series.

Immunotherapy in Patients With Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: A Multi-institutional Case Series.

Journal: Clinical lung cancer

Published: December 18, 2025

CLIP2::MET fusion identifies a molecularly distinct glioneuronal tumor.

CLIP2::MET fusion identifies a molecularly distinct glioneuronal tumor.

Journal: Discover oncology

Published: December 14, 2025

Elevated neutrophil-to-lymphocyte ratio as a prognostic factor in primary central nervous system lymphoma.

Elevated neutrophil-to-lymphocyte ratio as a prognostic factor in primary central nervous system lymphoma.

Journal: Neuro-oncology advances

Published: December 03, 2025

A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.

A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.

Journal: Journal of neuro-oncology

Published: December 03, 2025

First report of a clinical and radiologic response to vorasidenib in a patient with isocitrate dehydrogenase-mutant brainstem astrocytoma.

First report of a clinical and radiologic response to vorasidenib in a patient with isocitrate dehydrogenase-mutant brainstem astrocytoma.

Journal: Neuro-oncology practice

Published: October 29, 2025

The role of a multidisciplinary clinic for management of patients with IDH mutant gliomas.

The role of a multidisciplinary clinic for management of patients with IDH mutant gliomas.

Journal: Frontiers in oncology

Published: October 21, 2025

Polymorphic central nervous system (CNS) immune deficiency/dysregulation-associated lymphoproliferative disorders show a uniquely aggressive clinicopathologic profile compared to their extra-CNS counterparts.

Polymorphic central nervous system (CNS) immune deficiency/dysregulation-associated lymphoproliferative disorders show a uniquely aggressive clinicopathologic profile compared to their extra-CNS counterparts.

Journal: Human pathology

Published: October 14, 2025

Surgical Treatment of Brain Tumor-Related Epilepsy: Current and Emerging Strategies.

Surgical Treatment of Brain Tumor-Related Epilepsy: Current and Emerging Strategies.

Journal: Cancers

Published: October 06, 2025

Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.

Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.

Journal: Research square

Published: October 03, 2025

Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study.

Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study.

Journal: Blood

Published: September 30, 2025

Showing 1-12 of 60

Last Updated: 09/26/2026